ENSG
The Ensign Group, Inc.
ENSG has lower modeled downside risk, despite its lower overall score.
OSCR
Oscar Health, Inc.
OSCR has the edge over ENSG overall, supported by stronger fundamentals and stronger valuation.
ENSG Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Healthy | |
| Strong | |
| Strong |
ENSG's revenue, profitability, cash flow and balance sheet are all currently healthy.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
ENSG PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 22x | $187 | — |
| Cheap | 23x | $153 | -18% |
| Fair | 25x | $171 | -8.2% |
| Current | 28x | $187 | — |
| Expensive | 32x | $216 | +16% |
Historical ranges are pointers, not guarantees.
ENSG's PE is in its expensive range at 28x. If earnings grow as analysts expect, today's price would be 22x next year's earnings, in its cheap range.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR has the edge over ENSG in the historical PE scenario, which offers more potential upside but is not a forecast.
ENSG Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Growth | |
| Growth | |
| Stable | |
| Limited | |
| High |
Analysts expect earnings and revenue growth for ENSG, with profitability holding steady.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
OSCR has the edge over ENSG on the outlook, with more favorable profitability expectations.
ENSG Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $8.60 | +28% |
| Q3 2026 | $6.72 | +20% |
| Q2 2026 | $6.38 | +16% |
| Q1 2026 | $6.14 | +16% |
| Q4 2025 | $5.84 | +14% |
| Q3 2025 | $5.60 | +36% |
| Q2 2025 | $5.52 | +42% |
| Q1 2025 | $5.30 | +40% |
| Q4 2024 | $5.12 | +40% |
ENSG has the edge over OSCR on earnings, with more consistent year-over-year improvement.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has returned to profit: it earned $2.47 per share over the past year, after losing money the year before.
ENSG Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $1.5B | +14% |
| Q2 2026 | $1.4B | +17% |
| Q1 2026 | $1.4B | +18% |
| Q4 2025 | $1.4B | +20% |
| Q3 2025 | $1.3B | +20% |
| Q2 2025 | $1.2B | +18% |
| Q1 2025 | $1.2B | +16% |
| Q4 2024 | $1.1B | +15% |
ENSG's revenue has grown year over year every quarter since late 2020: $1.5B last quarter, up 14% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 9.3% | +1.9 points |
| Q2 2026 | 8.5% | 0 points |
| Q1 2026 | 9% | +0.3 points |
| Q4 2025 | 9.1% | +0.2 points |
| Q3 2025 | 7.4% | -0.8 points |
| Q2 2025 | 8.5% | +0.2 points |
| Q1 2025 | 8.6% | +0.5 points |
| Q4 2024 | 8.9% | +6.6 points |
ENSG has the edge over OSCR on profitability, with a higher operating margin.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR has the edge over ENSG on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR's operating margin was 3.5% last quarter, up 7.8 points from the same quarter a year ago.
ENSG Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $240.2M | +57% |
| Q2 2026 | $172M | +10% |
| Q1 2026 | $100.2M | +39% |
| Q4 2025 | $183.3M | +82% |
| Q3 2025 | $153M | +14% |
| Q2 2025 | $155.7M | +102% |
| Q1 2025 | $72.2M | +105% |
| Q4 2024 | $100.5M | +18% |
ENSG has the edge over OSCR on cash flow, with more consistent year-over-year improvement.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR usually generates cash, though not every quarter: the latest was −$1.2B, but it generated $4.1B over the past year.
ENSG Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.3% | -180K shares |
| 1 year | +0.6% | +347K shares |
| 3 years | +3.4% | +2M shares |
| 5 years | +4.1% | +2.3M shares |
| Available history | +5.9% | +3.3M shares |
ENSG has the edge over OSCR on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $7.4M |
| Q2 2026 | $40M |
| Q1 2026 | — |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | $9.2M |
| Q1 2025 | $10.8M |
| Q4 2023 | — |
ENSG spent $47M buying back its own shares over the past year.
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has 346M diluted shares, up 34% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
ENSG Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -0.2x | Net Cash |
| Q2 2026 | -0.2x | Net Cash |
| Q1 2026 | -0.7x | Net Cash |
| Q4 2025 | -0.7x | Net Cash |
| Q3 2025 | -0.6x | Net Cash |
| Q2 2025 | -0.5x | Net Cash |
| Q1 2025 | -0.3x | Net Cash |
| Q4 2024 | -0.7x | Net Cash |
ENSG has more cash than debt.
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has the edge over ENSG on leverage, with a lower net debt burden relative to earnings.
ENSG Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 59.6 | Neutral |
| Stochastic | 70.3 | Neutral |
ENSG's weekly RSI is 60 (neutral) and its Stochastic is 70 (neutral).
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
ENSG PE vs Healthcare Sector
| Metric | ENSG | Sector median | Relative |
|---|---|---|---|
| PE | 28x | 26x | 7.4% above |
| PE % | 66 | 29 | 37 pts above |
ENSG is trading at 28x earnings, in line with the Healthcare sector's median of 26x.
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR has the edge over ENSG on valuation relative to its sector.
ENSG Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $177.5 | 5.1% above |
| 20 week MA | $175.8 | 6.1% above |
| 50 week MA | $181.0 | 3.1% above |
| 100 week MA | $165.7 | 13% above |
| 200 week MA | $139.9 | 33% above |
ENSG is in an uptrend: it's above all five of its weekly moving averages, and 33% above its 200-week average.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR is in an uptrend: it's above all five of its weekly moving averages, and 106% above its 200-week average.
ENSG Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $44.7 | $72.8 | +63% |
| 2021 | $72.8 | $81.8 | +12% |
| 2022 | $81.8 | $95.0 | +16% |
| 2023 | $95.0 | $112.2 | +18% |
| 2024 | $112.2 | $134.0 | +19% |
| 2025 | $134.0 | $176.4 | +32% |
| 2026 YTD | $176.4 | $186.5 | +5.7% |
ENSG has finished every year since 2020 higher, and it's up 5.7% so far in 2026.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over ENSG on returns for 2026, with the stronger performance.